Logo

LRMR

Larimar Therapeutics, Inc.

LRMR

Larimar Therapeutics, Inc. • NASDAQ
$3.54 ▲ 0.28% (+0.01)
Market Cap $302.99 M
52w High $6.91
52w Low $1.61
Dividend Yield 0%
P/E -1.81
Volume 582.08K
Outstanding Shares 85.59M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $49.499M ▲ $-47.712M ▼ 0% $-0.61 ▼ $-47.624M ▼
Q2-2025 $0 $27.792M ▼ $-26.182M ▲ 0% $-0.41 ▲ $-27.705M ▲
Q1-2025 $0 $31.188M ▼ $-29.281M ▼ 0% $-0.46 ▼ $-31.1M ▲
Q4-2024 $0 $31.293M ▲ $-28.824M ▼ 0% $-0.45 ▼ $-31.216M ▼
Q3-2024 $0 $18.264M $-15.499M 0% $-0.24 $-18.19M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $175.435M ▲ $187.35M ▲ $48.312M ▲ $139.038M ▲
Q2-2025 $138.524M ▼ $149.988M ▼ $30.134M ▲ $119.854M ▼
Q1-2025 $157.526M ▼ $170.175M ▼ $25.904M ▼ $144.271M ▼
Q4-2024 $183.454M ▼ $200.225M ▼ $28.413M ▲ $171.812M ▼
Q3-2024 $203.707M $219.021M $20.621M $198.4M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-47.712M ▼ $-28.753M ▼ $33.019M ▲ $65.287M ▲ $69.553M ▲ $-28.776M ▼
Q2-2025 $-26.182M ▲ $-19.381M ▲ $18.842M ▲ $0 $-539K ▲ $-19.4M ▲
Q1-2025 $-29.281M ▼ $-26.54M ▼ $14.448M ▼ $0 ▼ $-12.092M ▼ $-26.589M ▼
Q4-2024 $-28.824M ▼ $-21.815M ▲ $19.197M ▼ $36K ▲ $-2.582M ▼ $-21.994M ▲
Q3-2024 $-15.499M $-24.546M $27.272M $30K $2.756M $-24.608M

Five-Year Company Overview

Income Statement

Income Statement Larimar is still a pure R&D biotech: it has no product revenue and has reported steady operating and net losses every year. The loss level has been fairly consistent, reflecting ongoing but controlled spending on clinical development rather than aggressive expansion. Per‑share losses have fluctuated, partly due to changes in share count, but the overall pattern is what you’d expect from a clinical‑stage company investing ahead of any commercial launch. The key point: the business is designed around future potential rather than current earnings, and profitability is not yet in sight.

Balance Sheet

Balance Sheet The balance sheet is small but relatively simple. The company holds a modest base of total assets, with cash representing a meaningful portion but not an overwhelming cushion. Debt is low, which reduces financial pressure, and shareholder equity remains positive, indicating that the company is still funded primarily by equity capital rather than borrowing. However, the overall scale of resources is limited, so the balance sheet depends on continued access to external funding as development progresses.

Cash Flow

Cash Flow Larimar consistently uses cash rather than generates it, as is typical for a clinical‑stage biotech with no product sales. Operating cash outflows track closely with reported losses, showing that most spending is tied to R&D and operations rather than large capital projects. There is essentially no capital expenditure burden, so cash use is driven mainly by clinical and corporate costs. The trend shows some improvement in cash burn over time, but the company will likely need additional capital raises to sustain trials and move toward potential commercialization.

Competitive Edge

Competitive Edge Larimar occupies a specialized niche in rare‑disease biotech, focusing on mitochondrial‑targeted protein replacement therapies. Its lead program for Friedreich’s ataxia uses a direct protein delivery approach that is different from the only currently approved treatment, aiming at the root cause of the disease rather than downstream effects. Regulatory designations such as Orphan Drug and Fast Track help reinforce its position and may offer advantages in development and potential market exclusivity. That said, reliance on essentially one lead asset in a competitive and evolving rare‑disease space creates concentration risk if clinical or regulatory outcomes disappoint.

Innovation and R&D

Innovation and R&D The company’s core innovation is its intracellular delivery platform designed to transport therapeutic proteins directly into mitochondria, which is technically challenging and potentially widely applicable. Nomlabofusp, the lead candidate, provides proof‑of‑concept for this platform in Friedreich’s ataxia, with clinical data showing biologic activity and multiple favorable regulatory designations. R&D is tightly focused: most value currently rests on advancing this single program through later‑stage trials and regulatory review, with future optionality from extending the platform to other rare diseases. The lack of a publicly detailed broader pipeline is both a risk, due to concentration, and an opportunity if additional programs are successfully launched off the same technology base.

Summary

Larimar is an early‑stage, science‑driven biotech without revenue, funded mainly through equity and focused spending on a single high‑potential rare‑disease program. Financially, the company runs predictable, controlled losses and steady cash burn, with a modest cash position and very little debt, which limits financial strain but underscores dependence on future financing. Strategically, its differentiation comes from a unique mitochondrial protein‑delivery platform and a lead asset that aims directly at the root cause of Friedreich’s ataxia, supported by favorable regulatory status. The upside case depends on successful clinical and regulatory milestones and eventual pipeline expansion, while key risks center on single‑asset dependence, ongoing cash needs, and the inherent uncertainty of late‑stage biotech development.

NEWS

November 5, 2025 · 7:00 AM UTC

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Read more

October 30, 2025 · 6:00 PM UTC

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR

Read more

October 28, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Read more

October 23, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Read more

October 22, 2025 · 12:16 PM UTC

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR

Read more